Bufexamac

SKU: orb1225540

Description

Bufexamac is a COX inhibitor for IFN-α release.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 2438-72-4
• MW: 223.27
• Purity: >98% (HPLC)
• Formula: C₁₂H₁₇NO₃
• SMILES: O=C(NO)CC1=CC=C(OCCCC)C=C1
• Target: COX
• Solubility: Ethanol: 3 mg/mL (13.43 mM); DMSO: 45 mg/mL (201.54 mM)

Bioactivity

• In Vivo:
  Animal model: Six-to-eight weeks old female C57BL/6 mice. Dosage: 50-100 mg/kg. Administration: Oral gavage (p.o.), seven days. Result: Ameliorated the infiltration of lung inflammatory cells and injury to the lung in a dose-dependent manner. Relieved LPS-induced lung injury. Reduced LTB4 level and MPO activity. Reduced cytokine mRNA expressions in lung tissue and cytokine levels in BALF in LPS-induced ALI in mice. Animal model: horses aged 2 to 7 years old and weighing 302 to 522 kg. Dosage: 20-100 mg. Administration: Intraarticular (IA) injection, weekly, 6 times. Result: Didn't effect on general health, hematological or serum biochemical variables, or organs.
  Read more...
• In Vitro:
  Cell Viability Assay Cell line: BE(2)-C cells. Concentration: 30 μM. Incubation time: 6 days. Result: Enhanced cell death of tumor cells. Cell Migration Assay Cell line: mouse neutrophils. Concentration: 50-100 μM. Incubation time: 30 min. Result: Reduced fMLP (5 μM) induced neutrophil migration. Western blot analysis. Cell line: Hela cells (ATCC: CCL-2). Concentration: 1 mM. Incubation time: 4-16 h. Result: Induced HIF1-α protein and increased HIF1-α levels. Immunofluorescence Cell line: Hela cells (ATCC: CCL-2). Concentration: 50-250 μM. Incubation time: 4 h. Result: Stabilized HIF1-α and accumulated in the nucleus.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Bufexamac | CP-1044-J-3 | CP 1044 J 3 | CP1044J3 | Droxaryl | Parfenac

Quick Database Links

Gene Symbol

COX